{'fraction_non_alphanumeric': 0.022935779816513763, 'fraction_numerical': 0.016819571865443424, 'mean_word_length': 4.5508474576271185, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
One step closer to a CMV vaccine.

In this issue of the Journal, Pass and colleagues describe the results of a phase 2 trial of a vaccine containing recombinant cytomegalovirus (CMV) glycoprotein B subunit antigen combined with MF59 adjuvant for the prevention of CMV infection in seronegative women of childbearing age.1 The primary end point was the time to CMV infection in the women. Their report of 50% vaccine efficacy (95% confidence interval, 7 to 73) is a promising development in the long search for an effective vaccine to protect against congenital CMV infection. CMV was first recognized as a cause of birth defects when the evaluation . . .